This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, D. Articles by Teh, B. T. Search for Related Content PubMed PubMed Citation Articles by Huang, D. Articles by Teh, B. T.

Inhibition of MAPK Kinase Signaling Pathways Suppressed Renal Cell Carcinoma Growth and Angiogenesis In vivo

¹ Laboratory of Cancer Genetics, ² Laboratory of Cancer and Developmental Cell Biology, and ³ Laboratory of Analytical, Cellular, and Molecular Microscopy, Laboratory of Microarray Technology, Van Andel Research Institute, Grand Rapids, Michigan; ⁴ Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; and ⁵ NCCS-VARI Translational Research Laboratory, National Cancer Center, Singapore, Singapore

Requests for reprints: Bin Tean Teh, Van Andel Research Institute, 333 Bostwick Avenue N.E., Grand Rapids, MI 49503. Phone: 616-234-5296; Fax: 616-234-5297; E-mail: Bin.Teh{at}vai.org.

The mitogen-activated protein kinase (MAPK) signaling pathways play essential roles in cell proliferation and differentiation. Recent studies also show the activation of MAPK signaling pathways in tumorigenesis, metastasis, and angiogenesis of multiple human malignancies, including renal cell carcinoma (RCC). To assess the role of this pathway in regulating the proliferation and survival of RCC cells, we first examined the expression of MAPK kinase (MKK) and MAPK in clear cell RCC and confirmed the overexpression of MKK1 and extracellular signal-regulated kinase 2 (ERK2) in these tumors. We then tested the effects of pharmacologic inhibition of MKK on human RCC cell lines, both in vitro and in vivo, using anthrax lethal toxin (LeTx), which cleaves and inactivates several MKKs. Western blotting showed that the phosphorylation levels of ERK, c-Jun-NH₂ kinase, and p38 MAPK decreased after 72 h of LeTx treatment. Exposure to LeTx for 72 h reduced cell proliferation by 20% without significant effects on cell cycle distribution and apoptosis. Anchorage-independent growth of RCC cells was dramatically inhibited by LeTx. In vivo studies showed that tumor growth of RCC xenografts could be suppressed by LeTx. Extensive necrosis and decreased tumor neovascularization were observed after LeTx treatment. LeTx also showed direct inhibition of proliferation of endothelial cells in vitro. Our results suggest that suppression of one or more MAPK signaling pathways may inhibit RCC growth through the disruption of tumor vasculature. [Cancer Res 2008;68(1):81–8]

This article has been cited by other articles:

				N. Tsukamoto, S. Okada, Y. Onami, Y. Sasaki, K. Umezawa, and Y. Kawakami Impairment of Plasmacytoid Dendritic Cells for IFN Production by the Ligand for Immunoglobulin-Like Transcript 7 Expressed on Human Cancer Cells Clin. Cancer Res., September 15, 2009; 15(18): 5733 - 5743. [Abstract] [Full Text] [PDF]

				R. W. Alfano, S. H. Leppla, S. Liu, T. H. Bugge, C. J. Meininger, T. C. Lairmore, A. F. Mulne, S. H. Davis, N. S. Duesbery, and A. E. Frankel Matrix Metalloproteinase-Activated Anthrax Lethal Toxin Inhibits Endothelial Invasion and Neovasculature Formation during In vitro Morphogenesis Mol. Cancer Res., April 1, 2009; 7(4): 452 - 461. [Abstract] [Full Text] [PDF]

				X. Pang, T. Yi, Z. Yi, S. G. Cho, W. Qu, D. Pinkaew, K. Fujise, and M. Liu Morelloflavone, a Biflavonoid, Inhibits Tumor Angiogenesis by Targeting Rho GTPases and Extracellular Signal-Regulated Kinase Signaling Pathways Cancer Res., January 15, 2009; 69(2): 518 - 525. [Abstract] [Full Text] [PDF]

				T. Yi, S.-G. Cho, Z. Yi, X. Pang, M. Rodriguez, Y. Wang, G. Sethi, B. B. Aggarwal, and M. Liu Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways Mol. Cancer Ther., July 1, 2008; 7(7): 1789 - 1796. [Abstract] [Full Text] [PDF]